Fischer, Aryeh <br/><br/>
Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.  [electronic resource] 

 -  Respiratory medicine  08 2016 
 - 254-63 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1532-3064 
<br/><br/><label>Standard No.: </label>10.1016/j.rmed.2016.06.018  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antihypertensive Agents--administration & dosage<br/>Connective Tissue Diseases--complications<br/>Double-Blind Method<br/>Endothelin A Receptor Antagonists--pharmacology<br/>Female<br/>Humans<br/>Hypertension, Pulmonary--complications<br/>Male<br/>Middle Aged<br/>Outcome Assessment, Health Care<br/>Phenylpropionates--administration & dosage<br/>Predictive Value of Tests<br/>Prevalence<br/>Pyridazines--administration & dosage<br/>Survival Analysis<br/>Treatment Outcome<br/>Walk Test--methods